B. Riley analyst Mayank Mamtani lowered the firm’s price target on Denali Therapeutics (DNLI) to $30 from $35 and keeps a Buy rating on the shares following the Q1 report. The firm updated the company’s model. FDA-related uncertainty continues to weigh on the stock, but attainment of regulatory and pipeline execution milestones in coming months, alongside visibility into new FDA leadership staff taking form, could bode well for Denali, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target lowered to $29 from $30 at Baird
- Denali Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
- Denali Therapeutics Advances Pipeline Amid Financial Loss
- Denali Therapeutics price target lowered to $30 from $32 at Wedbush
- Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright